ICDs extend the lives of heart attack survivors by an entire year: Study

May 14, 2009

A landmark follow-up study found that heart attack survivors who receive implanted cardioverter defribillators (ICDs) live longer the longer they have them, according to the results of late-breaking clinical trail presented today at the annual Scientific Sessions of the Heart Rhythm Society.

ICDs are devices designed to correct arrhythmias, electrical malfunctions that throw the out of rhythm and cause many of the sudden cardiac deaths each year in the United States. Most fatal arrhythmias in the aging are caused by scar tissue left behind by heart attacks that interferes with the heart's electrical system.

The study that first tested the effectiveness of ICDs, the 2002 MADIT II trial (Multicenter Automatic Defibrillator Implantation Trial II), changed medical guidelines nationwide and made thousands of heart attack survivors eligible for ICD therapy. Led by Arthur Moss, M.D., professor of Medicine in the Department of Medicine at the University of Rochester Medical Center, the study found that the devices reduced risk of by 31 percent in survivors. At the same time, the ICD therapy could extend the average patient's life by about two months over a follow-up period that averaged about 2 years per patient. While that survival benefit was meaningful to patients, some critics argued that it did not make sense for the healthcare system to pay for $25,000 a device that provided a modest extension of life in patients with chronic cardiac disease.

The current study watched the same patients for eight years, and found that over that time, patients with ICDs implant lived an average of more than a year longer, "greatly amplifying" the value of the treatment and arguing that it is dramatically more cost effective as a chronic therapy. Specifically, the new study found that MADIT II patients who had an ICD for eight years had a 37 percent lower chance of death from any cause than those without one, which translates into 1.2 life-years saved.

"These results show that ICDs extend the long-term survival of patients with life-threatening of heart conditions," said Ilan Goldenberg, M.D., research associate professor within the Heart Research Follow-up Program at the University of Rochester Medical Center, and lead author of the new study. "These results emphasize the life-saving value of ICDs as chronic therapy for high-risk cardiac .

Source: University of Rochester Medical Center (news : web)

Explore further: Better living through mitochondrial derived vesicles

add to favorites email to friend print save as pdf

Related Stories

Largest study to date finds benefits of ICDs in children

May 01, 2008

More and more children with congenital heart disease are receiving implantable cardioverter-defibrillators (ICDs) to maintain proper heart rhythm. ICDs were first introduced for adults in the 1980s, but little is known about ...

Defibrillators save lives, don't diminish quality of life

Sep 04, 2008

Implantable cardioverter-defibrillators (ICDs) reduce the risk of death from sudden cardiac arrest (SCA) among patients with heart failure, and they do so without significantly altering a person's quality of life, say researchers ...

Anger management: The key to staying heart healthy?

Feb 23, 2009

New research published in the March 3, 2009, issue of the Journal of the American College of Cardiology finds that anger-induced electrical changes in the heart can predict future arrhythmias in patients with implantable cardio ...

Recommended for you

Better living through mitochondrial derived vesicles

19 hours ago

(Medical Xpress)—As principal transformers of bacteria, organelles, synapses, and cells, vesicles might be said to be the stuff of life. One need look no further than the rapid rise to prominence of The ...

Zebrafish help to unravel Alzheimer's disease

20 hours ago

New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain. A new study by scientists at ...

Engineering new bone growth

23 hours ago

MIT chemical engineers have devised a new implantable tissue scaffold coated with bone growth factors that are released slowly over a few weeks. When applied to bone injuries or defects, this coated scaffold ...

User comments : 0